ROCKVILLE, Md.--(BUSINESS WIRE)--March 5, 2007--Emergent
BioSolutions Inc. (NYSE:EBS) announced today that it will present at
the Cowen and Company 27th Annual Health Care Conference in Boston.
Fuad El-Hibri, chairman and chief executive officer of Emergent
BioSolutions and Dr. Stephen N. Chatfield, chief scientific officer of
Emergent BioSolutions, will provide a company overview and outline
future growth opportunities at 3:10 pm EDT, Monday, March 12, 2007 at
The Boston Marriott Copley Place, Boston, Massachusetts.
A webcast of the presentation will be available both live and by
replay. To access both the live and archived webcast, please go to
www.emergentbiosolutions.com, click on the "Investors" link and
proceed to the "Webcasts & Presentations" section. The archived replay
will be available 24 hours after the live presentation and will be
accessible for 30 days.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused
on the development, manufacture and commercialization of
immunobiotics. Immunobiotics are vaccines and immune globulins that
induce or assist the body's immune system to prevent or treat disease.
The company's biodefense business is focused on developing and
commercializing immunobiotics for use against biological agents that
are potential weapons of bioterrorism. The company's commercial
business is focused on developing immunobiotics for use against
infectious diseases with significant unmet or underserved medical
needs. More information on the company is available at
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows, 301-795-1877
SOURCE: Emergent BioSolutions Inc.